Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY01005 Safety in Breast and Prostate Cancer
CTR20220490Phase 3Completed
- Sponsor
- Luye Pharma Group
- Start
- Mar 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of goserelin in breast cancer, prostate cancer (PCa), sponsored by Luye Pharma Group. Started Mar 2022; status: completed.
02
Drugs
goserelin
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20220490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220490.